Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 4
2021 2
2022 3
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
A role of FDG-PET/CT for response evaluation in metastatic breast cancer?
Hildebrandt MG, Naghavi-Behzad M, Vogsen M. Hildebrandt MG, et al. Semin Nucl Med. 2022 Sep;52(5):520-530. doi: 10.1053/j.semnuclmed.2022.03.004. Epub 2022 May 4. Semin Nucl Med. 2022. PMID: 35525631 Free article. Review.
It has also shown a higher predictive value than conventional CT when applying the respective response evaluation criteria, RECIST and PERCIST. Response categorization using FDG-PET/CT is more sensitive in detecting progressive and regressive disease, while conventi …
It has also shown a higher predictive value than conventional CT when applying the respective response evaluation criteria, RECIST an …
FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond.
Hildebrandt MG, Lauridsen JF, Vogsen M, Holm J, Vilstrup MH, Braad PE, Gerke O, Thomassen M, Ewertz M, Høilund-Carlsen PF; Centre for Personalized Response Monitoring in Oncology (PREMIO). Hildebrandt MG, et al. Cancers (Basel). 2019 Aug 15;11(8):1190. doi: 10.3390/cancers11081190. Cancers (Basel). 2019. PMID: 31443324 Free PMC article.
While current international guidelines include imaging of the target lesion for response monitoring in metastatic breast cancer, they do not provide specific recommendations for choice of imaging modality or response criteria. ...No studies have yet addressed …
While current international guidelines include imaging of the target lesion for response monitoring in metastatic breast cance …
Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation.
van Barele M, Akdeniz D, Heemskerk-Gerritsen BAM; Genepso; Andrieu N, Noguès C; HEBON; van Asperen CJ, Wevers M, Ausems MGEM, de Bock GH, Dommering CJ, Gómez-García EB, van Leeuwen FE, Mooij TM; EMBRACE; Easton DF, Antoniou AC, Evans DG, Izatt L, Tischkowitz M, Frost D, Brewer C, Olah E, Simard J, Singer CF, Thomassen M, Kast K, Rhiem K, Engel C, de la Hoya M, Foretová L, Jakubowska A, Jager A, Sattler MGA, Schmidt MK, Hooning MJ. van Barele M, et al. J Natl Cancer Inst. 2023 Nov 8;115(11):1318-1328. doi: 10.1093/jnci/djad116. J Natl Cancer Inst. 2023. PMID: 37369040 Free PMC article.
Response Monitoring in Metastatic Breast Cancer: A Prospective Study Comparing (18)F-FDG PET/CT with Conventional CT.
Vogsen M, Harbo F, Jakobsen NM, Nissen HJ, Dahlsgaard-Wallenius SE, Gerke O, Jensen JD, Asmussen JT, Jylling AMB, Braad PE, Vach W, Ewertz M, Hildebrandt MG. Vogsen M, et al. J Nucl Med. 2023 Mar;64(3):355-361. doi: 10.2967/jnumed.121.263358. Epub 2022 Oct 7. J Nucl Med. 2023. PMID: 36207136 Free PMC article.
This study aimed to compare contrast-enhanced CT (CE-CT) and (18)F-FDG PET/CT for response monitoring in metastatic breast cancer using the standardized response evaluation criteria RECIST 1.1 and PERCIST. ...Methods: Women with biopsy-verified metastatic bre …
This study aimed to compare contrast-enhanced CT (CE-CT) and (18)F-FDG PET/CT for response monitoring in metastatic breast can …
FDG-PET/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review.
Helland F, Hallin Henriksen M, Gerke O, Vogsen M, Høilund-Carlsen PF, Hildebrandt MG. Helland F, et al. Diagnostics (Basel). 2019 Aug 27;9(3):106. doi: 10.3390/diagnostics9030106. Diagnostics (Basel). 2019. PMID: 31461923 Free PMC article. Review.
18F-fluorodeoxyglucose positron emission tomography with integrated computed tomography (FDG-PET/CT) and contrast-enhanced computed tomography (CT) can be used for response evaluation in metastatic breast cancer (MBC). In this study, we aimed to review literature comparing …
18F-fluorodeoxyglucose positron emission tomography with integrated computed tomography (FDG-PET/CT) and contrast-enhanced computed tomograp …
2-[(18)F]FDG-PET/CT is a better predictor of survival than conventional CT: a prospective study of response monitoring in metastatic breast cancer.
Vogsen M, Naghavi-Behzad M, Harbo FG, Jakobsen NM, Gerke O, Asmussen JT, Nissen HJ, Dahlsgaard-Wallenius SE, Braad PE, Jensen JD, Ewertz M, Hildebrandt MG. Vogsen M, et al. Sci Rep. 2023 Apr 5;13(1):5552. doi: 10.1038/s41598-023-32727-w. Sci Rep. 2023. PMID: 37019987 Free PMC article.
The secondary objective was to assess agreement between response categorization for the two modalities. Treatment response in women with MBC was monitored prospectively by simultaneous CE-CT and 2-[(18)F]FDG-PET/CT, allowing participants to serve as their own …
The secondary objective was to assess agreement between response categorization for the two modalities. Treatment response in …
Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review.
Kavan S, Kruse TA, Vogsen M, Hildebrandt MG, Thomassen M. Kavan S, et al. Cancer Metastasis Rev. 2022 Jun;41(2):433-446. doi: 10.1007/s10555-022-10023-9. Epub 2022 Mar 14. Cancer Metastasis Rev. 2022. PMID: 35286542 Review.
We review tumor heterogeneity and clonal evolution from studies comparing primary tumors and metastasis and discuss plasma circulating tumor DNA as a powerful real-time approach for monitoring the clonal landscape of breast cancer during treatment and recurrence. ...Curren …
We review tumor heterogeneity and clonal evolution from studies comparing primary tumors and metastasis and discuss plasma circulating tumor …
A randomised trial of [18F]PSMA-1007-PET/CT versus NaF-PET/CT for staging primary prostate cancer: A trial protocol.
Buch-Olsen KM, Poulsen MH, Hansen S, Vilstrup MH, Holm J, Hess S, Holdgaard PC, Zieger KEA, Madsen SS, Gerke O, Pedersen KT, Dam JH, Langkjær N, Østergaard LD, Asmussen JT, Braad PE, Nørgaard B, Eiber M, Hildebrandt MG. Buch-Olsen KM, et al. BJUI Compass. 2023 May 12;4(5):513-522. doi: 10.1002/bco2.243. eCollection 2023 Sep. BJUI Compass. 2023. PMID: 37636207 Free PMC article.
STUDY DESIGN: This is a prospective randomised controlled multicentre trial carried out at three centres in the Region of Southern Denmark. ENDPOINTS: The primary endpoint is PFS. ...
STUDY DESIGN: This is a prospective randomised controlled multicentre trial carried out at three centres in the Region of Southern De …
17 results